METTL3 tagged as new AML target
CAMBRIDGE, U.K.—The journal Nature recently published data from STORM Therapeutics that links an essential RNA-modifying enzyme to acute myeloid leukemia (AML). The study identified the METTL3 gene as a new drug target for the disease. Inhibition of this gene was found to destroy mouse and human AML cells without damaging healthy blood cells, and METTL3 is necessary for AML cell survival and also regulates other leukemia genes. The results came from research STORM conducted together with Wellcome Trust Sanger Institute, The Gurdon Institute and Department of Pathology at the University of Cambridge and Cold Spring Harbor Laboratory.
Keith Blundy, CEO of STORM Therapeutics, said: “STORM leads the field of harnessing the power of RNA epigenetics as a new area of important biology. Our ambition is to become a world leading therapeutics company tackling diseases through modulating RNA modifying enzymes. Publication of these data, in such a prestigious journal as Nature, is validation of the world class science on which the Company was founded.”